FDA CRL Delays ViiV’s Long-Acting Cabotegravir Regimen

Manufacturing Questions Triggered FDA Complete Response Letter

ViiV Healthcare will not be able to launch its cabotegravir and rilpivirine long-acting HIV treatment in January after receiving an FDA Complete Response Letter.

Delay
Complete Response Letter Delays ViiV’s Planned 2DR Launch • Source: Shutterstock

The unexpected arrival of a complete response letter from the US Food And Drug Administration (FDA) means ViiV Healthcare will not be able to launch its long-acting double drug HIV-1 treatment next month, as it had confidently planned.

ViiV’s head of R&D Kimberly Smith had told Scrip in an interview earlier in December that FDA approval of the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip